Abstract | BACKGROUND: AIMS: A post-marketing surveillance study was conducted to evaluate the efficacy and safety of Desowen ( Desonide 0.05%) cream and lotion in Indian patients for the treatment of steroid-responsive dermatoses of mild to moderate severity. METHODS: A 3-week, multicenter, open-label, non-comparative Phase IV trial involving 1789 patients from 229 centers across India was conducted between January and August 2003. RESULTS: Of the 1789 patients, 1483 patients completed the treatment as per protocol. At the end of the therapy, 98.5% of the patients showed an improvement in their dermatitis from baseline. More than half of the patients showed a greater than 75% improvement in their signs and symptoms. No adverse effects were noted in any of the patients. Both the lotion and cream were found to be equally effective. CONCLUSIONS:
Desonide 0.05% is a safe and effective low-potency corticosteroid for the treatment of mild to moderate dermatoses in Indian patients. No clinically apparent side-effects were observed in infants less than 1 year of age.
|
Authors | Dimple A Bhankharia, Percy H Sanjana |
Journal | Indian journal of dermatology, venereology and leprology
(Indian J Dermatol Venereol Leprol)
2004 Sep-Oct
Vol. 70
Issue 5
Pg. 288-91
ISSN: 0973-3922 [Electronic] United States |
PMID | 17642640
(Publication Type: Journal Article)
|